PTC Therapeutics Inc
(STU:BH3)
€
36.8
0 (0%)
Market Cap: 2.89 Bil
Enterprise Value: 2.25 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 66/100 PTC Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 10, 2021 / 03:00PM GMT
Release Date Price:
€35.2
(-1.12%)
Jeffrey Hung
Welcome to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analysts. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have from PTC Therapeutics' CEO, Stuart Peltz; and Chief Development Officer Matthew Klein. Welcome.
Stuart W. Peltz
PTC Therapeutics, Inc. - Co-Founder, CEO & Executive Director
Thanks for having us.
Jeffrey Hung
Thank you. For those who may not be familiar with PTC, can you provide a brief introduction?
Stuart W. Peltz
PTC Therapeutics, Inc. - Co-Founder, CEO & Executive Director
Yes, sure. Well, first, thanks for having us. We appreciate the opportunity to be here. For those who don't know us, we're -- I founded the company, so I
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot